Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge
- PMID: 32349886
- PMCID: PMC7185008
- DOI: 10.1016/j.schres.2020.04.030
Long-acting injectable antipsychotics treatment during COVID-19 pandemic - A new challenge
Conflict of interest statement
Declaration of competing interest None of the authors have conflicts to report.
Comment in
-
Long acting injectable antipsychotic medications: Ensuring care continuity during the COVID-19 pandemic restrictions.Schizophr Res. 2020 Aug;222:532-533. doi: 10.1016/j.schres.2020.05.001. Epub 2020 May 7. Schizophr Res. 2020. PMID: 32389613 Free PMC article. No abstract available.
References
-
- Kane J.M., Kishimoto T., Correll C.U. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J. Clin. Epidemiol. 2013;66(8 Suppl):S37–S41. doi: 10.1016/j.jclinepi.2013.01.012. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical